Citadel Advisors
SKYE icon

Citadel Advisors’s Skye Bioscience SKYE Stock Holding History

Citadel Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Sell
39,100
-25,600
-40% -$20.9K ﹤0.01% 12631
2025
Q4 		$48.5K Buy
64,700
+36,500
+129% +$53.3K ﹤0.01% 12050
2025
Q3 		$111K Sell
28,200
-5,200
-16% -$19.6K ﹤0.01% 11776
2025
Q2 		$140K Buy
+33,400
New +$69.1K ﹤0.01% 11023
2025
Q1 		– Sell
-100
Closed -$283 – 15760
2024
Q4 		$283 Sell
100
-8,000
-99% -$33.4K ﹤0.01% 14355
2024
Q3 		$31.7K Buy
8,100
+7,000
+636% +$39.3K ﹤0.01% 12381
2024
Q2 		$8.81K Buy
+1,100
New +$13.1K ﹤0.01% 13165

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's SKYE Position: Q4 2025 in Review

Citadel Advisors sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 28,852 shares — an estimated $42.1K sold.

Citadel Advisors first reported a position in SKYE in Q2 2024 and held it in 4 quarters. The position peaked at $2.13M in Q2 2024. 50 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Citadel Advisors reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 28,852 Skye Bioscience shares in Q4 2025, an estimated $42.1K.
  • Citadel Advisors first reported a position in Skye Bioscience in Q2 2024 and held it in 4 quarters.
  • Citadel Advisors's Skye Bioscience position peaked at $2.13M in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.